BioNTech SE Sponsored ADR (NASDAQ:BNTX) Receives Consensus Rating of “Moderate Buy” from Brokerages

Shares of BioNTech SE Sponsored ADR (NASDAQ:BNTX) have been assigned a consensus rating of “Moderate Buy” from the sixteen brokerages that are covering the stock, MarketBeat reports. One investment analyst has rated the stock with a sell rating, four have given a hold rating and eleven have issued a buy rating on the company. The average 1-year target price among brokers that have covered the stock in the last year is $140.1029.

BNTX has been the topic of a number of recent research reports. Leerink Partners downgraded BioNTech from an “outperform” rating to a “market perform” rating and set a $113.00 target price on the stock. in a report on Monday, February 2nd. Jefferies Financial Group reissued a “buy” rating and issued a $151.00 price objective on shares of BioNTech in a report on Wednesday, December 3rd. UBS Group upgraded shares of BioNTech to a “hold” rating in a research report on Thursday, December 4th. The Goldman Sachs Group upgraded shares of BioNTech from a “neutral” rating to a “buy” rating and increased their price target for the stock from $115.00 to $142.00 in a research report on Friday, January 16th. Finally, HC Wainwright reissued a “buy” rating and set a $140.00 price objective on shares of BioNTech in a research report on Thursday, December 11th.

Institutional Trading of BioNTech

Hedge funds and other institutional investors have recently bought and sold shares of the stock. Invesco Ltd. lifted its position in shares of BioNTech by 9.0% during the 4th quarter. Invesco Ltd. now owns 80,841 shares of the company’s stock valued at $7,696,000 after buying an additional 6,685 shares in the last quarter. Alberta Investment Management Corp bought a new stake in BioNTech during the 4th quarter worth approximately $1,021,000. Krensavage Asset Management LLC lifted its holdings in BioNTech by 25.4% during the fourth quarter. Krensavage Asset Management LLC now owns 99,523 shares of the company’s stock valued at $9,475,000 after purchasing an additional 20,157 shares in the last quarter. Mackenzie Financial Corp boosted its position in shares of BioNTech by 4.5% in the fourth quarter. Mackenzie Financial Corp now owns 4,485 shares of the company’s stock worth $428,000 after purchasing an additional 195 shares during the period. Finally, XTX Topco Ltd increased its stake in shares of BioNTech by 90.4% in the fourth quarter. XTX Topco Ltd now owns 28,180 shares of the company’s stock worth $2,683,000 after purchasing an additional 13,382 shares in the last quarter. Hedge funds and other institutional investors own 15.52% of the company’s stock.

BioNTech Stock Performance

BNTX stock opened at $110.42 on Friday. The company has a market cap of $24.86 billion, a P/E ratio of -41.98 and a beta of 1.49. BioNTech has a 1 year low of $81.20 and a 1 year high of $124.00. The company has a debt-to-equity ratio of 0.01, a current ratio of 7.12 and a quick ratio of 7.02. The stock’s fifty day moving average price is $103.88 and its 200-day moving average price is $103.56.

BioNTech Company Profile

BioNTech SE (NASDAQ: BNTX) is a Germany-based biotechnology company that develops next-generation immunotherapies and vaccines, with a primary focus on messenger RNA (mRNA) technology. Founded in 2008 and headquartered in Mainz, BioNTech advances a platform approach to design and manufacture therapeutics across oncology, infectious diseases and other high unmet-need areas. The company is publicly traded on the NASDAQ exchange and became widely known for its rapid development and global deployment of an mRNA-based COVID-19 vaccine in collaboration with Pfizer.

BioNTech’s core activities include discovery research, clinical development and manufacturing of mRNA-based medicines, personalized cancer immunotherapies, engineered cell therapies, and antibody- and protein-based therapeutics.